Business
BullFrog AI Announces Exclusive, Worldwide Licensing Agreement with Johns Hopkins’ Applied Physics Laboratory for Patented AI Technology
Licensed technology powers BullFrog’s bfLEAP™ - one of the most innovative, technologically advanced analytics engines - to streamline therapeutics
About this update from Bullfrog Ai Holdings, Inc.
[{"type":"text","content":"Licensed technology powers BullFrog’s bfLEAP™ - one of the most innovative, technologically advanced analytics engines - to streamline therapeutics development\nGAITHERSBURG, Md., April 04, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) (\"Bullfrog AI\" or the \"Company\"), a digital technology company using machine learning to usher in a new era of precision medicine, is pleased to announce its worldwide license agreement with Johns Hopkins University Applied Physics Laboratory (“APL”) for use of patented technology powering the Company’s bfLEAP™ platform. BullFrog’s bfLEAP™ platform analyzes drug development data to potentially make life-saving therapies and treatments available to patients more quickly. The patented technology from APL includes analytical models that enable the analysis and interpretation of large, complex, and diverse datasets that may be incomplete and comprise both numerical and categorical data and provide explainable results. The innovative technology, which enables the detection of anomalies, patterns, and relationships, has been shown to perform better than well-known algorithms in benchmarking tests. “The ability to make predictions with incomplete multimodal data and insufficient scalability of digital analytics are two critical issues for researchers and clinicians today,” said Vin Singh, Founder and CEO of BullFrog AI. “With the help of John Hopkins APL’s patented technology, our bfLEAP™ platform is able to overcome these challenges, enabling precise identification of meaningful data for more agile drug development. We are excited to apply this game-changing technology to both our internal drug development and clinical testing initiatives, as well as in strategic relationships with key partners in biopharma.” BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need. The licensed technologies from APL include Prometheus and Seagull. Prometheus includes a comprehensive library of APL-invented probabilistic models, one of which recently beat 10 competing algorithms in detecting anoma...